This research aims to evaluate the effects of omitting hyperthermic intraperitoneal chemotherapy (HIPEC) during treatment for colorectal peritoneal metastases (CPM).
Evaluated short-term oncologic outcomes after cytoreductive surgery (CRS) with and without HIPEC.
Compared morbidity associated with each treatment approach.
Analyzed long-term benefits of HIPEC, if any.
Omission of HIPEC did not result in significant morbidity.
Short-term oncologic benefits were found to be equivalent between groups.
Long-term benefits of HIPEC remain uncertain.
Abstract
CRS with mitomycin-HIPEC can be considered for treatment of CPM without significant morbidity and equivalent short-term oncologic benefits. However, the long-term benefit of HIPEC remains unclear.